真正偶然发现低级别胶质瘤的队列分析
该回顾性队列研究在两家欧洲神经外科中心分析2015-2019年管理的150例WHO II级肿瘤,其中82例为症状性弥漫性低级别胶质瘤,20例为偶然发现。偶然发现低级别胶质瘤多为IDH突变和少突胶质细胞瘤,与症状性相比总生存有改善趋势且无进展生存显著延长(P=0.024)。无论表现如何,全切除较活检显著改善无进展生存和总生存。
要点
- 偶然发现低级别胶质瘤多为IDH突变和少突胶质细胞瘤。
- 偶然发现较症状性低级别胶质瘤无进展生存显著延长(P=0.024)。
- 全切除较活检显著改善无进展生存和总生存。
核心结论
- 偶然发现与症状性低级别胶质瘤在特征和生存上存在差异,但因偶然发现低级别胶质瘤罕见、样本量小而未达显著。
- 需要进一步的全球合作和建立国际胶质瘤登记库,重点关注症状、影像指征(如偶然发现)、组织分子数据和管理。
研究设计与样本
- 回顾性队列分析,纳入2015-2019年在皇家维多利亚医院和明斯特大学医院管理的低级别胶质瘤。
- 偶然发现严格定义为因常规临床或研究影像而发现、与占位性病变检查无关且无相关症状。
- 共识别150例WHO II级肿瘤,其中82例为症状性弥漫性低级别胶质瘤,20例为偶然发现;48例非弥漫性和/或儿童肿瘤被排除。
主要发现
- 偶然发现低级别胶质瘤多为IDH突变和少突胶质细胞瘤。
- 与症状性低级别胶质瘤相比,偶然发现低级别胶质瘤总生存有改善趋势,无进展生存显著延长(P=0.024)。
- 所有病例中,全切除较活检显著改善无进展生存(风险比0.45,95%置信区间0.21-0.95,P=0.037)和总生存(风险比0.10,95%置信区间0.02-0.44,P=0.003)。
关键数值与推荐
- 偶然发现低级别胶质瘤与症状性低级别胶质瘤的无进展生存比较P=0.024。
- 全切除较活检的无进展生存风险比0.45(95%置信区间0.21-0.95),P=0.037。
- 全切除较活检的总生存风险比0.10(95%置信区间0.02-0.44),P=0.003。
临床怎么用
- 原文未据此给出推荐。
局限性
- 偶然发现低级别胶质瘤罕见且样本量小,导致偶然发现与症状性低级别胶质瘤之间的差异不显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Management of low-grade gliomas (LGGs) is controversial. Incidental LGGs are thought to represent an earlier stage in the disease process compared with symptomatic LGGs. With advanced imaging techniques, the discovery of these lesions is expected to increase, resulting in clinical need for further understanding of these tumors. This study aimed to identify the incidence of incidental LGGs across 2 large European neurosurgical centers and review management and survival of tumors compared with symptomatic cranial LGGs over a 5-year period. METHODS: LGGs managed during 2015-2019 at the Royal Victoria Infirmary and Münster University Hospital were retrospectively reviewed. An incidental finding was strictly defined as one discovered secondary to routine clinical or research imaging, not associated with investigation for a space-occupying lesion, with no associated symptoms. All histomolecular pathology reports were reviewed. RESULTS: Of 150 cases of World Health Organization grade II tumors identified at both centers, 82 were symptomatic, diffuse LGGs, with 20 discovered incidentally. There were 48 nondiffuse and/or pediatric tumors, which were excluded. Incidental LGGs were mostly IDH mutated and oligodendroglial with a trend toward improved overall survival and significantly increased progression-free survival compared with symptomatic LGGs (P = 0.024). In all cases, regardless of presentation, progression-free survival and overall survival were significantly improved following gross total resection versus biopsy (hazard ratio 0.45 [95% confidence interval 0.21-0.95], P = 0.037 vs. hazard ratio 0.10 [95% confidence interval 0.02-0.44], P = 0.003). CONCLUSIONS: In this study, differences in characteristics and survival between incidental and symptomatic LGGs were present, yet not significant owing to the rarity, and therefore small sample size, of incidental LGGs. Further global collaboration and development of an international glioma registry with a focus on symptoms, imaging indications (if incidental), histomolecular data, and management are needed.
引用
- Allison CM, Shumon S, Stummer W, et al. A Cohort Analysis of Truly Incidental Low-Grade Gliomas. World Neurosurg. 2021. PMID: 34942387. doi:10.1016/j.wneu.2021.12.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。